Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Electronic Arts Inc. (EA) vs Merck & Co., Inc. (MRK) Price & Performance

Electronic Arts Inc.Trade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Electronic Arts Inc. vs Merck & Co., Inc. — how do they compare? Electronic Arts Inc. trades at $207.26 (market cap $51.97B), while Merck & Co., Inc. trades at $128.04 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 5.9× Electronic Arts Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.75%). Which is the better fit depends on your goals.

EAMRK
Market Cap
$51.97B$305.29B
Sector
TechnologyHealth
52-Week High
$207.27$129.52
52-Week Low
$147.79$77.60
Enterprise Value
$50.54B$348.71B
Dividend Yield
0.37%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Electronic Arts Inc.

Electronic Arts (EA) trades at $206.65, showing modest daily gains of 0.15%. The stock exhibits a bullish technical structure with moving averages aligned positively, though oscillators signal caution with RSI levels above 70. Fundamentally, EA maintains strong profitability with 78.97% gross margins and 11.78% net income margins, but valuation metrics appear elevated with a P/E of 59.05 and P/S of 6.96. Recent business developments include the successful launch of EA SPORTS College Football 27 and the introduction of EA Advertising platform for in-game brand integration.

The outlook balances strong franchise execution against valuation concerns. Investment opportunities stem from EA's dominant gaming portfolio, recurring revenue streams, and new advertising monetization. Key risks include recent earnings misses, potential regulatory scrutiny of the rumored $55 billion Saudi acquisition (Reuters, June 24, 2026), and stretched valuation multiples that may limit near-term upside despite analyst consensus leaning positive.

Merck & Co., Inc.

Merck (MRK) trades at $128.00, up 5.96% on the day. The stock shows a bullish technical signal with strong moving average support, while fundamentals reveal robust profitability with a 73.91% gross margin and consistent earnings beats in recent quarters. The company is actively expanding its oncology pipeline through acquisitions, most notably the $6.7 billion tender offer for Terns Pharmaceuticals announced in April 2026.

The outlook is positive, supported by strong analyst consensus (67.57% Buy rating) and a price target implying ~7% upside. Key opportunities include pipeline expansion via M&A and solid cash flow generation. Primary risks involve integration of large acquisitions, patent cliffs for key drugs, and intense competition in the oncology space, which could pressure future growth margins.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Electronic Arts Inc.

EA is one of the world's largest third-party video game publishers and has transitioned from a console-based video game publisher to the one of the largest publishers on consoles, PC, and mobile. The firm owns number of large franchises, including Madden, FIFA, Battlefield, Apex Legends, Mass Effect, Dragon's Age, and Need for Speed.

Read more on EA

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK